Department of Neurology, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Regen Med. 2011 Jan;6(1):45-52. doi: 10.2217/rme.10.97.
To assess the safety and feasibility of intra-arterial transplantation of autologous bone marrow mononuclear cells in patients with middle cerebral artery ischemic stroke within 90 days of symptom onset.
PATIENTS & METHODS: Six patients were included in the study, and they received 1-5 × 10(8) bone marrow mononuclear cell and were evaluated using blood tests, neurological and imaging examination before treatment, and 1, 3, 7, 30, 60, 90, 120 and 180 days after transplantation. Scintigraphies were carried out 2 and 24 h after the procedure to analyze the biodistribution of labeled cells. Electroencephalogram was conducted within 7 days after transplantation.
No patients exhibited any complication or adverse events during the procedure. There was no worsening in the neurological scales until the end of the follow-up.
Intra-arterial bone marrow mononuclear cell transplantation is feasible and safe in patients with nonacute ischemic strokes of the middle cerebral artery. Further studies are required to evaluate the efficacy of this therapy.
评估在症状出现后 90 天内对大脑中动脉缺血性脑卒中患者进行自体骨髓单个核细胞动脉内移植的安全性和可行性。
本研究纳入了 6 名患者，他们接受了 1-5×10(8)个骨髓单个核细胞，并在治疗前、治疗后 1、3、7、30、60、90、120 和 180 天进行了血液检查、神经学和影像学评估。在手术结束后 2 和 24 小时进行闪烁扫描以分析标记细胞的生物分布。在移植后 7 天内进行脑电图检查。
在手术过程中，没有患者出现任何并发症或不良事件。在随访结束时，神经量表没有恶化。
对于大脑中动脉非急性缺血性脑卒中患者，经动脉内骨髓单个核细胞移植是可行和安全的。需要进一步的研究来评估这种治疗的疗效。
